Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex^TM, when given as monotherapy during daily dosing of 10–200 mg to patients with advanced prostate cancer.Methods: A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex. The doses ranged from 10 to 200 mg. Objective assessments of efficacy included: review of measurable metastases, prostate dimension, prostatic acid phosphatase and prostate-specific antigen (PSA) levels. Subjective assessments of efficacy included review of urological symptoms, performance status, bone scan and analgesic requirement. Pharmacokinetic samples were taken at various time points up to 3 months, and assayed using an achiral HPLC method.Results: Clear objective responses were observed, particularly at doses of 50 mg and above. Specifically, the median percentage decrease in PSA at 50 mg was 90.0%, and at 100 and 200 mg it was 93.4 and 94.8%, respectively. Up to 53% of symptomatic patients demonstrated a subjective response at 3 months. Casodex was well tolerated at all doses with no effect on haematological or cardiovascular parameters and no effect on renal function. The expected pharmacological effects of potent antiandrogen therapy, such as breast tenderness (58%), gynaecomastia (48%), and hot flushes (17%), were reported, but these incidences reflected the direct eliciting of these events. The intrinsic efficacy of Casodex was demonstrated despite increases of 60% in testosterone levels. However, this increase reached a plateau after 4–12 weeks of therapy, but the majority of values remained within the normal range. Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics.Conclusion: Casodex has a favourable side effect profile compared with the known safety profiles of other antiandrogens and has demonstrated intrinsic efficacy. Casodex warrants further investigation as a monotherapy for the management of advanced prostate cancer.

Keywords:

Casodex,Monotherapy,Dose-ranging,Advanced prostate cancer,Pharmacokinetics

References

Cancer Research Campaign: Factsheet 1994;20:1–6.

Denis LJ, Whelan P, Carneiro de Moura JL, Newling D, Bono A, De Pauw M, Sylvester R: Goserelin acetate and flutamide versus bilateral orchidectomy: A Phase III EORTC trial. Urology 1993;42:119–130.

Delaere KPJ, Van Thillo EL: Flutamide monotherapy as primary treatment in advanced prostate cancer. Semin Oncol 1991;18(suppl 6):13–18.

Macfarlane JR, Tolley DA: Flutamide therapy for advanced prostate cancer: A Phase II study. Br J Urol 1985;57:172–174.

Sogani PC, Vagaiwala MR, Whitmore WF: Experience with flutamide in patients with advanced prostate cancer without prior endocrine therapy. Cancer 1984;54:744–750.

Narayan P, Trachtenberg J, Lepor H, Debruyne FMJ, Tewari A, Stone N, Das S, Jimenez-Cruz JF, Shearer R, Klimberg I, Schellhammer PF, Costello AJ: A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multi-centre study. Urology 1996;47:497–504.

Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, Gilbert RH: FLutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996;199:451–455.

Wysowski DK, Fourcroy JL: Fatal hepatotoxicity. J Urol 1996;155:209–212.

Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MA, Constantini M, Giuliani L: Monotherapy with nilutamide, a pure non-steroidal anti-androgen in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377–381.

10.

Chatelain C, Rousseau V, Cosaert J: Monotherapy with castration plus nilutamide in metastatic prostate cancer: A preliminary report. Eur Urol 1994;26(suppl 1):10–14.

11.

Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L: The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990;18(suppl 3):10–17.

12.

Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.

13.

Lunglmayr G: Casodex (ICI 176,334), a new non-steroidal antiandrogen. Early clinical results. Horm Res 1989;32(suppl 1):77–81.

14.

Mahler C, Denis L: Clinical profile of a new non-steroidal antiandrogen. J Steroid Biochem Mol Biol 1990;37:921–924.

15.

Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, Mattelaer J, D’Hulster D, Mahler Ch: Endocrine profiles during administration of the new nonsteroidal antiandrogen Casodex in prostate cancer. Clin Endocrinol 1994;41:525–530.

16.

Furr BJA: Casodex: Preclinical studies. Eur Urol 1990;18(suppl 3):2–9.

17.

Cockshott ID, Sotaniemi EA, Cooper KJ, Jones DC: The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol 1993;36:339–343.

18.

Blackledge G, Kolvenbag G, Nash A: Bicalutamide: A new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anticancer Drugs 1996;7:27–34.

19.

Lee M, Ngan J, Ransone C, Sharifi R: Elevated serum testosterone levels during Casodex treatment: Is it clinically significant? Ther Drug Monit 1993;15:137.

20.

Mahler C, Denis L: Clinical profile of a new non-steroidal antiandrogen. J Steroid Biochem Mol Biol 1990;37:921–924.

21.

Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Vogelzang NJ, Kennealey GT: Bicalutamide (50 mg) in the treatment of advanced prostatic carcinoma: A Phase II noncomparative multicentre trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995;154:2110–2114.

22.

Blackledge GRP, Lowery K: Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate 1994;(suppl 5):34–38.

23.

Kaisary AV: Current clinical studies with a new non-steroidal antiandrogen, Casodex. Prostate 1994;(suppl 5):27–33.

24.

Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F: Casodex – An acceptable monotherapy for advanced prostate cancer? Preliminary results of a randomised trial against castration. Urology 1992;587–590.

25.

Blackledge G: Clinical progress with a new antiandrogen, Casodex (bicalutamide). Eur Urol 1996;29(suppl 2):96–104.

26.

Kolvenbag GJCM, Blackledge GRP: Worldwide activity and safety of bicalutamide: A summary review. Urology 1996;47(suppl 1A):70–79.

27.

Lunglmayr G: Efficacy and tolerability of Casodex in patients with advanced prostate cancer. Anticancer Drugs 1995;6:1–7.

28.

Tyrrell CJ: Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. Eur Urol 1994;26(suppl 1):15–19.

29.

Moller S, Iversen P, Franzmann M-N: Flutamide-induced liver failure. J Hepatol 1990;10:346–349.

30.

McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA: Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993;23:1241–1253.

31.

O’Malley K, Crooks J, Duke E, Stevenson IH: Effect of age and sex on human drug metabolism. Br Med J 1971;iii:607–609.

32.

Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F: A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 1995;28:215–222.

33.

Sharafi R, Chodak G, Venner P, Block N, Calahan-Squire M, Jones J: Casodex versus castration in treatment of stage D2 prostate cancer: Prostate-specific antigen as a measure of outcome. Proc Am Soc Clin Oncol 1993;12:241.

34.

Iversen P, Tverer K, Varenhorst E: Randomised study of Casodex 50 mg monotherapy versus orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996;30:93–98.

35.

Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(suppl 1A):38–43.

1998

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

You do not currently have access to this content.